Gerbu Adjuvant

Story
Types
Ingredients
Dosing
References

Story

Story In 1991 Dr. Nikolaus Grubhofer started research to make his vision come true. He decided to develop a better adjuvant, which meant: match Freund’s adjuvant as the yardstick of efficiency, make it perfectly biotolerable, remove the emulsion handling problem, maintain a reasonable price level and get it patented and licensed. Many data and formulations have become available as the result of the 50 years of scientific work following Freund. The trouble with all this work was that it was done nearly exclusively with mice and was of very limited use with larger animals, which were the necessary models for veterinary and human vaccination.

In 2001 the GERBU Adjuvant (GA) formulations basically were ready¹: A nanosuspension of cationized lipid solid particles in water combined with GMDP² and other synergists. They could be simply mixed with the antigen solution and were as strongly effective as Freund’s FCA, also in other host animals such as sheep, goats, cattle and humans - but devoid of its drawbacks: They were completely biocompatible and easy to use, suitable for licensing in pharmaceutical use.

After more than 10 years of development and field tests, GA have emerged as the only efficient, biocompatible, convenient and economical successors of adjuvants as Freund’s or Alumina. Various patents have been granted and our Adjuvants are produced in GMP facilities.

Types

Laboratory Adjuvants For research and antibody production. Just mix with antigen and inject	Vaccine Adjuvants For immunological research and experimental use. Please inquire!
GA MM For monoclonal antibody production. Specially developed formulation for best yield of fused clones in mice.	GA Veterinary For large scale vaccination of pigs and cattle / poultry.
GA LQ Universal lab quality, mainly for antibody production. Extremely robust formula for optimum T1 and T2 effect with less sensitive animals like mice, rabbits, chicken. Highly concentrated potentiator of cellular and humoral immune response with long term protection effect. Very mild, no local reactions.	GA Pharma Biocompatible and extremely effective, mainly for vaccination. For treating particularly sensitive animals such as horses and camels, potentially also for human pharmaceutical use. High concentration for small injection volumes. A powerful potentiator of cellular and humoral immune response with long-term protecting effect. All components are non-toxic and pharmacologically accepted. It is a nanosuspension of cationic lipid in aqueous medium. Particularly simple to handle, just mix with antigen and inject
GA 10 / GA 100 Predosed 0.5 / 5 ml – Our “classic” adjuvant, for small animals and polyclonal antibody production e.g. in rabbits. Extremely powerful Freund’s-like TH1 action, devoid of local symptoms.

Ingredients

3 Synergistic Factors at work:

Factor 1: Cationic Nanoparticles in a colloidal suspension replace the classic water-in-oil emulsion. They bind the antigen and immediately carry it to the lymphocytes for phagocytosis. There is no local depot and of course no granuloma. Their composition makes them immunostimulating, they are slowly biodegradable and non-irritant. Ideal for high humoral titers.

Factor 2: GMDP the adjuvant glycopeptide derived from L. bulgaricus cell walls. GMDP replaces the mycobacteria in FCA. GMDP² is a powerful immunomodulator and is completely devoid of local reactions upon injection. It is pyrogenic and somnogenic in larger doses. It induces T-cell response and long-lasting cellular immunity³.

Factor 3: Immunomodulators Cimetidine as a histamine antagonist has been found to generally enhance immune response. Also contains Saponin, an efficient unspecific stimulator of the immune system.

Table 2: GA Composition

Table 3: Dosing and application

References

1 Grubhofer Nikolaus (1995). An adjuvant formulation based on GMDP and DDA synergist. Immunology Letters 44: 19-24

2 Johannsen L, Rosenthal RS, Martin SA, Cady AB, Obal Jr. F, Guinand M, Krueger JM (1989). Somnogenic activity of O-acetylated and dimeric muramyl dipeptides. Infect. Immun., 57(9):2726-2732.

3 Levi M, Rudén U, Birx D, Loomis L, Redfield R, Lövgren K, Akerblom L, Sandström E, Wahren B (1993). Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. J Acquir Immune Defic Syndr., 6(8):855-864.